Berenberg Bank Reaffirms "Buy" Rating for Molten Ventures (LON:GROW)

Berenberg Bank reiterated their buy rating on shares of Molten Ventures (LON:GROW - Free Report) in a research note published on Thursday, Marketbeat.com reports. Berenberg Bank currently has a GBX 580 ($7.73) price objective on the stock.

Molten Ventures Price Performance

Shares of GROW stock traded down GBX 5 ($0.07) during trading hours on Thursday, reaching GBX 265.40 ($3.54). The company's stock had a trading volume of 2,616,939 shares, compared to its average volume of 1,340,856. Molten Ventures has a fifty-two week low of GBX 215.60 ($2.87) and a fifty-two week high of GBX 432.50 ($5.76). The firm's 50 day simple moving average is GBX 269.30 and its 200-day simple moving average is GBX 308.98. The company has a quick ratio of 4.37, a current ratio of 197.67 and a debt-to-equity ratio of 7.15. The company has a market capitalization of £493.93 million, a price-to-earnings ratio of -14.84 and a beta of 1.25.

Insider Activity at Molten Ventures

In other news, insider Andrew Zimmermann purchased 1,739 shares of the company's stock in a transaction dated Wednesday, March 26th. The stock was bought at an average cost of GBX 286 ($3.81) per share, for a total transaction of £4,973.54 ($6,626.97). Also, insider Benjamin David Wilkinson acquired 16,258 shares of the business's stock in a transaction that occurred on Friday, February 28th. The shares were purchased at an average cost of GBX 306 ($4.08) per share, for a total transaction of £49,749.48 ($66,288.45). Insiders have acquired 20,208 shares of company stock valued at $6,166,556 over the last ninety days. 8.56% of the stock is owned by corporate insiders.

Molten Ventures Company Profile

Molten Ventures is one of the most active venture capital firms in Europe, developing and investing in disruptive, high growth technology companies. We believe it is our role to support the visionary entrepreneurs who will invent the future. We fuel their growth with our ‘energy' in the form of truly patient capital, access to international networks and decades of experience building businesses.